GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Repaglinide (Prandin) tablets

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Prandin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Prandin - product and source limitations

There are no study data for CrCl below 20 or hemodialysis in this source. Skip the dose when a meal is skipped.

Before applying: Verify the current prescribing information for this presentation.

Also check: Prandin - product and source limitations

Official source

Prandin - labeled renal guidance

Renal action and limits

Repaglinide (Prandin), adult oral tablets for type 2 diabetes
Creatinine clearance (CrCl), mL/min; use the product-specific calculation

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
At CrCl 20-40 mL/min start with 0.5 mg before each meal. Titrate gradually to glucose response.
Limits and monitoring
There are no study data for CrCl below 20 or hemodialysis in this source. Skip the dose when a meal is skipped.
Before use
Verify the current prescribing information for this presentation.

DailyMed SPL version 5, effective 2017-12-28; posted Dec 28, 2017 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Repaglinide (Prandin), adult oral tablets for type 2 diabetes
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 5, effective 2017-12-28; posted Dec 28, 2017
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2 and 8, renal impairment

At CrCl 20-40 mL/min start with 0.5 mg before each meal. Titrate gradually to glucose response. There are no study data for CrCl below 20 or hemodialysis in this source. Skip the dose when a meal is skipped.

Source revision: DailyMed SPL version 5, effective 2017-12-28; posted Dec 28, 2017 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=813f781f-7db8-49ed-b4ed-a829c37eddb7

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Prandin - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Repaglinide (Prandin), adult oral tablets for type 2 diabetes

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Prandin - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Repaglinide (Prandin), adult oral tablets for type 2 diabetes

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Prandin - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Prandin - product and source limitations

There are no study data for CrCl below 20 or hemodialysis in this source. Skip the dose when a meal is skipped.

How to use this: Verify the current prescribing information for this presentation.

Prandin - labeled renal guidancePrandin - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePrandin - labeled renal guidancePrandin - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

Renal Insufficiency: Initial dose adjustment does not appear to be necessary for patients with mild to moderate renal dysfunction. However, patients with type 2 diabetes who have severe renal function impairment should initiate PRANDIN therapy with the 0.5 mg dose - subsequently, patients should be carefully titrated. Studies were not conducted in patients with creatinine clearances below 20 mL/min or patients with renal failure requiring hemodialysis.

GRPH-general-repaglinide-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Prandin - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Repaglinide (Prandin), adult oral tablets for type 2 diabetes

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date: DailyMed SPL version 5, effective 2017-12-28; posted Dec 28, 2017
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2 and 8, renal impairment

At CrCl 20-40 mL/min start with 0.5 mg before each meal. Titrate gradually to glucose response. There are no study data for CrCl below 20 or hemodialysis in this source. Skip the dose when a meal is skipped.

RDM73-prandin-official-1 · Source locator: Renal guidance: 2 and 8, renal impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=813f781f-7db8-49ed-b4ed-a829c37eddb7
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date/version
DailyMed SPL version 5, effective 2017-12-28; posted Dec 28, 2017
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e1add3bf4cd3e9df52c5b92422ce1ad26e168b997107d971b60cbc0f36521efc
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Prandin - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Repaglinide (Prandin), adult oral tablets for type 2 diabetes

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror gives the premeal starting dose in the 20-40 mL/min group.

RDM73-prandin-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/prandin-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
313d8336ced4dd2a8998edb3426b6ae4b322b8f68ab4c792b79b2538c27606ca

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 25
Local text SHA-256
528ec6913824a274f696a7d8a4687ebf718e1f20dc9ec6105de444183a4f1139
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top